Swedbank AB Has $1.13 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Swedbank AB decreased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 40.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 8,297 shares of the company’s stock after selling 5,715 shares during the period. Swedbank AB’s holdings in Neurocrine Biosciences were worth $1,133,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Commerce Bank boosted its holdings in Neurocrine Biosciences by 2.6% in the 3rd quarter. Commerce Bank now owns 4,199 shares of the company’s stock valued at $484,000 after purchasing an additional 108 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Neurocrine Biosciences by 2.7% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,302 shares of the company’s stock worth $496,000 after acquiring an additional 113 shares during the period. Brooklyn Investment Group boosted its position in shares of Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after acquiring an additional 115 shares in the last quarter. Tealwood Asset Management Inc. increased its stake in Neurocrine Biosciences by 1.0% in the fourth quarter. Tealwood Asset Management Inc. now owns 11,911 shares of the company’s stock valued at $1,626,000 after acquiring an additional 118 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB increased its stake in Neurocrine Biosciences by 42.0% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock valued at $72,000 after acquiring an additional 157 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on NBIX. Wedbush reaffirmed an “outperform” rating and issued a $148.00 target price on shares of Neurocrine Biosciences in a report on Monday, December 16th. Piper Sandler reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. HC Wainwright reissued a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 16th. UBS Group raised their price target on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a research note on Thursday. Finally, William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $166.10.

Neurocrine Biosciences Stock Down 1.0 %

NBIX opened at $151.82 on Monday. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The company has a fifty day moving average of $136.97 and a 200-day moving average of $131.42. The stock has a market cap of $15.37 billion, a PE ratio of 40.70 and a beta of 0.33.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the sale, the insider now directly owns 2,507 shares in the company, valued at approximately $338,445. The trade was a 30.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jude Onyia sold 2,331 shares of the stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the transaction, the insider now owns 15,449 shares in the company, valued at $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 214,799 shares of company stock valued at $31,513,583. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.